Greve J W M, Bouvy N D
Zuyderland Medisch Centrum, afd. Chirurgie, Heerlen.
Ned Tijdschr Geneeskd. 2018;162:D2268.
The EndoBarrier (duodenal-jejunal bypass liner) became available in 2009 as an endoscopic treatment method for obesity and type 2 diabetes mellitus (T2D). The treatment results in significant weight loss and improvement of the obesity-related morbidities such as T2D, non-alcoholic steatohepatitis, hypertension and other cardiovascular diseases. However, unexpected complications such as liver abscesses can occur, in addition to expected adverse events such as bleeding, obstruction, and migration. The incidence of these complications is low however, and to date no treatment-related mortality has occurred with the use of EndoBarrier. After more than 3800 procedures, it can be concluded that the EndoBarrier is safe and effective. This treatment option can be applied in patients with a BMI over 30 kg/m2 and also obese patients with T2D who do not wish to undergo, or are not fit for, a surgical procedure.
EndoBarrier（十二指肠-空肠旁路内衬）于2009年问世，作为一种治疗肥胖症和2型糖尿病（T2D）的内镜治疗方法。该治疗可显著减轻体重，并改善与肥胖相关的病症，如T2D、非酒精性脂肪性肝炎、高血压和其他心血管疾病。然而，除了出血、梗阻和移位等预期不良事件外，还可能发生肝脓肿等意外并发症。不过，这些并发症的发生率较低，迄今为止，使用EndoBarrier尚未发生与治疗相关的死亡病例。在进行了超过3800例手术后，可以得出结论，EndoBarrier是安全有效的。这种治疗方案可应用于体重指数超过30 kg/m2的患者，以及不希望接受手术或不适合接受手术的肥胖T2D患者。
